Surgical resection of metastatic pancreatic cancer: is it worth it?—a 15-year experience at a single Chinese center

• DOI: 10.21037/jgo.2020.03.02
• Publication Date: 2020-04-24T09:30:26Z
• Authors: Jiangning Gu; Zhiwei Xu; Yang Ma; Hao Chen; Di Wang; Xiaxing Deng; Dongfeng Cheng; Junjie Xie; Jiabin Jin; Xi Zhan; Yuan Shi; Yusheng Shi; Youwei Zhu; Baiyong Shen; Chenghong Peng
• Keywords: Single Center; Surgical resection

Background: The significance of surgical resection in the treatment metastatic pancreatic ductal adenocarcinoma (PDAC) is currently unclear. This study aimed to summarize and clarify experience M1 PDAC our center evaluate whether it may offer benefits some patients. Methods: We analyzed data patients with who underwent synchronous tumor between 2003 2014 at Ruijin Hospital. Simultaneously, clinical for palliative bypass or exploratory laparotomy only was also collected during same period as control. Every patient followed up least 3 years after hospitalization. follow-up endpoint December 31, 2017. Results: A total 36 resection; them, 7 received postoperative adjuvant chemotherapy. Their 1-, 2-, 3-year survival rates were 27.3%, 21.2%, 7.1%, respectively, overall 7.9 months. groups 4 3.7 months, respectively (P<0.05). Conclusions: It unclear can benefit due heterogeneity differences burden. However, current indicated that be safely performed might appropriate highly selected relatively longer time. Combined (neo)adjuvant chemotherapy would further prolong these